UK Pharmacovigilance Inspectors Report Drop In Critical Findings For Third Year In Row
Executive Summary
For the first time in nearly a decade, UK pharmacovigilance inspectors have not issued any critical findings in relation to reference safety information, but RSI continues to draw major findings.
You may also be interested in...
UK MHRA Takes Companies To Task Over Trial Safety Information Reporting
Sponsors of clinical trials in the EU have recently been inundated with objections from regulators for incorrectly managing their clinical trial reference safety information, which in turn has resulted in these trials being significantly delayed. A UK MHRA inspector discusses some of the common issues identified during inspections on this front.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.